Scarica l'app Stockscreener
35.60
4.35%
-1.62
Dopo l'orario di chiusura:
35.45
-0.15
-0.42%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
Barclays Lowers CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $42.00 - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Purchased by Benjamin Edwards Inc. - MarketBeat
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - MSN
CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks - MSN
2 Biotech Stocks That Are Screaming Buys in May - Yahoo Finance
Chardan Capital Issues Optimistic Forecast for CRSP Earnings - MarketBeat
Equities Analysts Set Expectations for CRSP Q2 Earnings - MarketBeat
Q2 EPS Estimate for CRISPR Therapeutics Raised by Analyst - MarketBeat
Needham & Company LLC Has Lowered Expectations for CRISPR Therapeutics (NASDAQ:CRSP) Stock Price - MarketBeat
CRISPR Therapeutics (CRSP) to Release Quarterly Earnings on Wednesday - MarketBeat
Chardan Capital Has Lowered Expectations for CRISPR Therapeutics (NASDAQ:CRSP) Stock Price - MarketBeat
Can Buying CRISPR Therapeutics and Holding It Forever Make You a Millionaire? - AOL.com
Can Buying CRISPR Therapeutics and Holding It Forever Make You a Millionaire? - The Motley Fool
CRISPR Therapeutics (CRSP) to Release Earnings on Wednesday - Defense World
William Blair Expects Lower Earnings for CRISPR Therapeutics - MarketBeat
Leerink Partnrs Issues Pessimistic Outlook for CRSP Earnings - MarketBeat
(CRSP) Investment Report - news.stocktradersdaily.com
Bridgefront Capital LLC Invests $680,000 in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Illinois Tool Works, Wynn Resorts, Agree Realty, Crispr Therapeutics, Super Micro Computer: Trending by Analysts - MSN
Dimensional Fund Advisors LP Boosts Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Chardan Capital Cuts CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $82.00 - Defense World
Crispr Therapeutics (CRSP) Price Target Reduced by Barclays to $42 | CRSP Stock News - GuruFocus
CRISPR Therapeutics (CRSP) Downgraded Amid Market Challenges - GuruFocus
CRISPR Therapeutics (CRSP) Price Target Lowered by Barclays | CRSP Stock News - GuruFocus
Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines - Seeking Alpha
Baker BROS. Advisors LP Has $51.48 Million Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NasdaqGM:CRSP) Q1 2025 Revenue Increases 71% to US$1 Million - Yahoo Finance
CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results - insights.citeline.com
CRISPR Therapeutics (CRSP): Goldman Sachs Lowers Price Target to $47 | CRSP Stock News - GuruFocus
June 27th Options Now Available For CRISPR Therapeutics - Nasdaq
Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet - Yahoo Finance
CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade) - Seeking Alpha
Promising Developments and Pipeline Expansion at Crispr Therapeutics AG Support Buy Rating - TipRanks
Chardan Capital Remains a Buy on Crispr Therapeutics AG (CRSP) - The Globe and Mail
CRSP: Needham Maintains Buy Rating Despite Target Price Reductio - GuruFocus
Crispr Therapeutics Q1 Earnings Analysis: Ignore The Gloom, Stay The Course (NASDAQ:CRSP) - Seeking Alpha
CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst - Benzinga
CRSP Sees Price Target Adjustment by BofA Amid Key Updates | CRS - GuruFocus
Crispr Therapeutics price target lowered to $79 from $80 at BofA - TipRanks
CRSP Sees Price Target Adjustment by BofA Amid Key Updates | CRSP Stock News - GuruFocus
CRSP: Needham Maintains Buy Rating Despite Target Price Reduction | CRSP Stock News - GuruFocus
These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results - Benzinga
CRSP Stock: Analyst Maintains Buy Rating, Lowers Price Target | CRSP Stock News - GuruFocus
Crispr Therapeutics AG: Promising Trial Results and Strong Financial Position Support Buy Rating - TipRanks
Crispr Therapeutics AG: Strong Buy Rating Backed by Promising Clinical Data and Strategic Collaborations - TipRanks
VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates - MSN
Crispr Therapeutics (CRSP) Upgraded to Buy by Clear Street Analyst | CRSP Stock News - GuruFocus
Crispr Therapeutics upgraded to Buy from Hold at Clear Street - TipRanks
Crispr Therapeutics AG: Balancing Growth Potential with Profitability Challenges – Hold Rating - TipRanks
NKureCRISPR Therapeutics partner to develop off-the-shelf CAR-T therapy - BusinessLine
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Stifel Financial Corp - Defense World
NkureCrispr Therapeutics partner to co-develop off-the-shelf CAR-T therapy - BusinessLine
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):